Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.23M+124% | $11.08M+317% | $621K+104% | -$1.93M+87.2% | -$9.22M+51.4% | ||
| $337K+7.0% | $335K+7.0% | $338K+10.1% | $325K+15.7% | $315K-3.4% | ||
| $4.14M-6.8% | $5.27M+46.6% | $7.64M+12.9% | $5.01M+18.3% | $4.44M+17.9% | ||
| $9.87M+198% | $20.04M— | $18.43M+322% | $182K+102% | -$10.03M+50.6% | ||
| -$325K-2,400% | -$333K-103% | -$71K— | -$279K— | -$13K+99.9% | ||
| -$8.84M-182% | —— | $13.85M— | —— | -$3.14M-109% | ||
| $708K+105% | $19.44M+56.9% | $32.21M+2,011% | $845K+117% | -$13.18M-177% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
